The EEA1 Knockout MES-OV Polyclonal Cells represent a polyclonal population of the MES-OV ovarian endometrioid carcinoma cell line engineered with CRISPR/Cas9 to disrupt the EEA1 gene. This heterogeneous pool of knockout cells provides a ready-to-use loss-of-function model for studying early endosome biology in the context of ovarian cancer, without the need for single-cell cloning.
The MES-OV host cell line was established from a human ovarian endometrioid adenocarcinoma and is extensively employed as an in vitro model for ovarian carcinoma. These adherent epithelial cells retain key features of endometrioid cancer, making them suitable for investigating tumor cell signaling, endocytic trafficking, and therapeutic response mechanisms.
EEA1 encodes an early endosome autoantigen 1 protein that functions as a tethering factor essential for homotypic fusion of early endosomes. It is recruited to endosomal membranes through concurrent binding to RAB5-GTP and phosphatidylinositol 3-phosphate (PI3P) via its C-terminal FYVE domain. EEA1 coordinates vesicle docking and fusion by interacting with SNARE proteins, including Syntaxin 13 and Syntaxin 6, and serves as a scaffold for Rab5 effectors such as Rabaptin-5. Upstream regulators include RAB5 and SRC kinase, while key downstream cargoes encompass the EGF receptor (EGFR) and transferrin receptor. Disruption of EEA1 impedes endosome maturation and cargo sorting, altering the degradation and recycling trajectories of internalized receptors.
In the MES-OV ovarian cancer background, EEA1-mediated endosomal trafficking is integral to the regulation of EGFR signaling and autophagy pathways, both frequently dysregulated in endometrioid carcinomas. Loss of EEA1 disrupts the normal processing of endocytosed EGFR, potentially prolonging downstream signaling and affecting cell proliferation and survival. This knockout model thus allows precise interrogation of how early endosome fusion events influence oncogenic networks and endosomal escape mechanisms that contribute to drug resistance in ovarian cancer.
This polyclonal knockout product is ideally suited for a range of functional assays, including fluorescent transferrin uptake to monitor endocytosis, EGFR degradation time-course analyses via immunoblotting, immunofluorescence co-localization studies with RAB5 and Syntaxin 13, and LC3-II flux assays to assess autophagic activity. Additionally, the model can be applied to investigate endosomal involvement in chemotherapy resistance and the trafficking of therapeutic nanoparticles. For further technical information and support, please contact Ascent Research.
